Katiutschka Reyes
Family · Rogers, ARNPI 1912258393
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Dexcom, Inc.$867
- Novo Nordisk$715
- Boehringer Ingelheim$516
- Medtronic$516
- Lilly USA, LLC$463
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,949100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 84 | $1,883 |
| Dexcom, Inc. | 49 | $867 |
| Novo Nordisk | 49 | $715 |
| Boehringer Ingelheim | 29 | $516 |
| Medtronic | 14 | $516 |
| Lilly USA, LLC | 19 | $463 |
| Sanofi-aventis U.S. LLC | 24 | $382 |
| Tandem Diabetes Care, Inc. | 11 | $369 |
| Amgen(2 entities) | 22 | $350 |
| AstraZeneca(2 entities) | 15 | $272 |
| AbbVie | 10 | $213 |
| Sequel Med Tech, LLC | 5 | $202 |
| Merck | 9 | $159 |
| Recordati_rare_diseases_inc. | 3 | $159 |
| Radius Health, Inc. | 7 | $147 |
| Insulet Corporation | 5 | $116 |
| Corcept Therapeutics | 4 | $99 |
| Halozyme Inc | 3 | $63 |
| Ascendis Pharma Endocrinology Inc | 3 | $62 |
| Bayer | 3 | $56 |
| Amryt Pharma Holdings Ltd | 3 | $49 |
| Mannkind Corporation | 2 | $48 |
| Cequr Corporation | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Averitas Pharma Inc. | 2 | $41 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
| Antares Pharma, Inc. | 2 | $30 |
| Chiesi USA, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$733
- DEXCOM G7 GSS (161)$250
- FREESTYLE LIBRE 3$212
- TWIIST$144
- MINIMED 780G$118
- MOUNJARO$113
How this compares
$7,949 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 517 | $688,573 |
| JardianceEmpagliflozin | 335 | $355,651 |
| MounjaroTirzepatide | 193 | $232,924 |
| Tresiba Flextouch U-200Insulin Degludec | 237 | $218,829 |
| FarxigaDapagliflozin Propanediol | 129 | $138,186 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 61 | $114,488 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 117 | $101,211 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $82,271 |
| TrulicityDulaglutide | 36 | $60,096 |
| Humalog Kwikpen U-100Insulin Lispro | 117 | $53,812 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $50,352 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $44,716 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 240 | $37,551 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $34,315 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $33,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Levemir | $715 | $716,674609 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $516 | $373,894354 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $463 | $305,571299 claims |
| AstraZenecaFarxiga | $272 | $138,186129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $382 | $22,91428 claims |
| MerckJanumet | $159 | $7,13211 claims |
| AbbVieSynthroid | $213 | $5,29162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Rogers
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.